Optimizing Survival in Advanced Prostate Cancer

By sponsoring the satellite symposium "Optimizing Survival in Advanced Prostate Cancer", Sanofi wants to contribute to further research in the management of prostate cancer.

Faculty:
Cora Sternberg, Italy – Chair
Theo de Reijke, The Netherlands – Chair
Stéphane Oudard, France
Christopher Sweeney, USA
Dear colleagues,

The therapeutic armamentarium to manage patients with advanced prostate cancer, in particular those with metastatic castration-resistant prostate cancer (mCRPC), has considerably expanded in the last few years.

The availability of novel therapies has increased the complexity of managing mCRPC patients. Indeed, the optimal sequence of these therapies is unknown and is likely to vary between individual patients, reflecting the heterogeneity of the disease. In addition, there is a rising concern of cross-resistance among the various mCRPC treatments.

Also, in newly diagnosed hormone-naïve metastatic prostate cancer, for years managed by androgen deprivation therapy (ADT), new data on an alternative treatment strategy has recently become available. The recent data suggest that upfront chemotherapy combined with ADT could improve survival compared with ADT alone*.

Physicians are challenged to integrate these new therapeutic options rationally in daily practice, in order to optimize treatment outcomes and benefits of each individual patient.

The objectives of this symposium include (1) to better understand prostate cancer heterogeneity to guide treatment choices, (2) to discuss the current and emerging treatment options in advanced prostate cancer, and (3) to discuss the clinical implications of early chemotherapy in castration-sensitive disease.

We look forward to seeing you in Madrid on Friday 20 March 2015.

Dr. Cora N. Sternberg and Dr. Theo de Reijke
Chairs

---

* Sweeney C et al. J Clin Oncol 2014;32(Suppl) abstract LBA2

### Optimizing Survival in Advanced Prostate Cancer

**Friday 20 March 2015, 16:15-17:45, Room Milan**

#### Topics & Faculty:

**Chairmen:**
- Cora Sternberg, Rome, Italy
- Theo de Reijke, Amsterdam, The Netherlands

16:15-16:20  **Welcome and introduction**  
*Theo de Reijke, Amsterdam, The Netherlands*

16:20-16:35  **Advanced prostate cancer: achievements and perspectives**  
*Theo de Reijke, Amsterdam, The Netherlands*

16:35-16:55  **Putting prostate cancer heterogeneity into perspective**  
*Cora Sternberg, Rome, Italy*

16:55-17:10  **mCRPC: integrating new learnings to optimize patient outcomes**  
*Stéphane Oudard, Paris, France*

17:10-17:30  **CHAARTED results: implications for the future**  
*Christopher Sweeney, Boston, MA, USA*

17:30-17:45  **Discussion and closing remarks**  
*Cora Sternberg, Rome, Italy*